Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

 

 

 

 

 

 

 

 

 

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company's cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.

This content is available to members only.

If you are an existing member, please LOGIN

Note a member? Sign up for a FREE trial account ($195 per month value), and get immediate access. Free offer expires May 29, 2019.

Register New Account

Free Membership

.

Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2
subscribe@wallstreetreporter.com.